Clinical trials for rcc
WebMar 20, 2024 · Approaches to Dosing TKIs in Patients with Advanced RCC. EP: 8. COSMIC-313 Trial of Cabozantinib, Nivolumab and Ipilimumab in Frontline Advanced RCC. EP: 9. Phase III Trial of Lenvatinib, Pembrolizumab, and Belzutifan or Quavonlimab in Frontline Advanced RCC. Now Viewing. WebNov 6, 2024 · A phase 3, randomized, active-controlled trial will evaluate the efficacy and safety of a HIF-2α inhibitor for the second-line treatment of clear cell RCC.
Clinical trials for rcc
Did you know?
WebClinical Trial Page; ... and safety of AK104 in combination with axitinib as a first-line treatment for advanced/metastatic specific subtypes of renal cell carcinoma (ssRCC). Subjects will receive AK104 plus axitinib until disease progression, development of unacceptable toxic effects, death, a decision by the physician or patient to withdraw ... WebApr 14, 2024 · Lindy G. Durrant, Fayaz Masters, Samantha Paston, Robert Miller, David J. Pinato, Rebecca Herbertson, Anne Armstrong, Stefan Symeonides, Christian Ottensmeier; Abstract CT256: Modi-1, anti-citrullinated neoepitope vaccine alone and combined with checkpoint inhibitors in patients with head and neck, breast, renal and ovarian …
WebApr 9, 2024 · Ultrafiltration has garnered interest as an alternative to diuretics after multiple randomised clinical trials demonstrated greater fluid removal and reduced neurohormonal activation [3,4,5,6,7].While its adoption within clinical practice has been limited, prior meta-analyses have showcased its advantage in rehospitalisation rates (absolute risk … WebSep 28, 2024 · Known distant metastasis at time of enrollment (with the exception of participants with limited/resectable stage IV cutaneous melanoma or RCC) Is participating in a clinical trial or another observational study that is evaluating the performance of another genomic test in the post-treatment surveillance setting at predicting/detecting recurrence
WebApr 11, 2024 · This is a Phase Ib/II, open-label, single arm trial to evaluate the efficacy and safety of AK104 in combination with axitinib as a first-line treatment for advanced/metastatic specific subtypes of renal cell carcinoma (ssRCC). WebJun 18, 2024 · A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC) ... Contact: Clinical Trials +1 (877) 214-4634: [email protected]: Locations. Layout table for location information; United States, California: Research Site 2:
WebApr 15, 2024 · A DLT consists of one or more of the following toxicities: (1) Grade 3 or 4 hypoxia or dyspnea (2) Grade 3 or 4 nausea, vomiting, or diarrhea if persistent for >48 hours despite therapy (3) Grade 3 or 4 cardiovascular, vascular, or thrombotic events (4) Nonhematologic AE ≥Grade 3 in severity (5) Grade 4 nonhematologic toxicity (6) Grade …
WebSep 13, 2024 · A clinical trial to compare the effectiveness of savolitinib plus durvalumab versus sunitinib in MET-driven (hepatocyte growth factor receptor), unresectable and locally advanced or metastatic PRCC (Papillary Renal Cell Carcinoma) Condition or disease Intervention/treatment netscape became firefoxWebSep 28, 2016 · The primary object is to estimate the Objective response rate (ORR) based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of the TITAN regimen in untreated (1st line) and pretreated (2nd line) subjects with International Metastatic RCC Database Consortium (IMDC) intermediate and high risk, … netscape 9.0 downloadWebDec 12, 2024 · A broad look at the data from several recent first-line clinical trials in the setting of advanced renal cell carcinoma and considerations for how they may impact real-world practice. EP: 1. Advanced Renal Cell Carcinoma: An Evolving Treatment Armamentarium. EP: 2. Factors in Selecting First-Line Therapy for Patients With … netscape 7 download